menu

RCC Treatment Strategies in a Poor-Risk Patient

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

RCC Treatment Strategies in a Poor-Risk Patient

close
0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.

    After viewing the activity, visit the Related tab for supplemental resources.

  • Disclosure of Conflicts of Interest

    Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:

    Oguz Akin, MD
    Ownership/Equity: Ezra AI 

    Robert Motzer, MD
    Consultant (occasional): AstraZeneca, Aveo, Eli Lilly, EMD Serrono, Exelexis, Genentech/Roche, Merck
    Trial support: Easai, Exelexis, Genentech/Roche, Merck

    Jay Raman, MD, FACS
    Trial support: MDx Health, Pacific Edge Biotechnologies, Urogen Pharma
    Investment interest: United Medical Systems, Inc. 

    Elizabeth Plimack, MD, MS
    Consultant (occasional): AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, Seattle Genetics

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
    Lenvatinib/pembolizumab combination therapy for advanced RCC

    ACHL, Penn State College of Medicine staff, and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

  • Target Audience

    This activity is intended for medical oncologists, nephrologists, genitourinary cancer specialists, and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss the major clinical trials that support the use of TKIs and immunotherapy for ccRCC
    • Explain considerations for selecting a first-line treatment regimen for a patient with ccRCC, including biomarkers, adverse events, and medical comorbidities
    • Apply clinical trial evidence and available recommendations to formulate tailored treatment regimens for advanced RCC
    • Describe techniques and strategies for establishing shared decision-making in the selection of treatment for RCC
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageReachMD Healthcare Image

    Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Penn State College of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Penn State College of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This activity is supported by independent medical education grants from Exelixis, Inc., and Merck & Co., Inc..

  • Method of Participation

    This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6760-22-T.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.

    After viewing the activity, visit the Related tab for supplemental resources.

  • Disclosure of Conflicts of Interest

    Penn State College of Medicine requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:

    Oguz Akin, MD
    Ownership/Equity: Ezra AI 

    Robert Motzer, MD
    Consultant (occasional): AstraZeneca, Aveo, Eli Lilly, EMD Serrono, Exelexis, Genentech/Roche, Merck
    Trial support: Easai, Exelexis, Genentech/Roche, Merck

    Jay Raman, MD, FACS
    Trial support: MDx Health, Pacific Edge Biotechnologies, Urogen Pharma
    Investment interest: United Medical Systems, Inc. 

    Elizabeth Plimack, MD, MS
    Consultant (occasional): AstraZeneca, Aveo, Bristol-Myers Squibb, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, Seattle Genetics

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
    Lenvatinib/pembolizumab combination therapy for advanced RCC

    ACHL, Penn State College of Medicine staff, and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

  • Target Audience

    This activity is intended for medical oncologists, nephrologists, genitourinary cancer specialists, and other healthcare professionals involved in the care or treatment of patients with RCC such as oncology nurses, nurse practitioners, and physician assistants.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss the major clinical trials that support the use of TKIs and immunotherapy for ccRCC
    • Explain considerations for selecting a first-line treatment regimen for a patient with ccRCC, including biomarkers, adverse events, and medical comorbidities
    • Apply clinical trial evidence and available recommendations to formulate tailored treatment regimens for advanced RCC
    • Describe techniques and strategies for establishing shared decision-making in the selection of treatment for RCC
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare ImageReachMD Healthcare Image

    Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Penn State College of Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Penn State College of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This activity is supported by independent medical education grants from Exelixis, Inc., and Merck & Co., Inc..

  • Method of Participation

    This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    Questions regarding accreditation can be directed to ContinuingEd@pennstatehealth.psu.edu or 717-531-6483. Refer to course number G6760-22-T.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/25/21